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Abstract
Background: The management of inflammatory bowel disease in patients who have previously undergone liver transplant-
ation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating
such immuno-compromised patients.
Objective: We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety.
Methods: PubMed/Embase/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipi-
ents and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and
inflammatory bowel disease outcomes.
Results: Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow-up
time ranging from 5–20 months. No malignancies were reported. Inflammatory bowel disease clinical response was
experienced by 20/26 patients. Abnormalities in liver tests were recorded in 2/22 patients.
Conclusion: Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients.
Caution is recommended for patients with an unstable liver graft function.
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Background
The therapeutic management of inflammatory bowel
disease (IBD) in patients who had previously under-
gone a liver transplant (LT) can be a real clinical chal-
lenge because of the increased risk of infectious events
in transplant recipients.1
These patients are not anecdotal as around 5%
of IBD patients develop primary sclerosing
cholangitis (PSC).2 This is a chronic fibro-inflammatory
disorder which lacks effective treatment and can result
in end-stage liver disease and need for a liver
transplantation.2
The natural course of the IBD after liver transplant-
ation is still unpredictable. In a systematic review by
Singh et al.,3 39% of patients showed no significant
change in IBD course compared with their pre-liver
transplantation IBD activity. Otherwise, one-third
of patients may have a paradoxical worsening of
their bowel symptoms in spite of immunosuppressive
therapy.
Nevertheless, there are serious concerns among
physicians regarding the use of biologic agents
for treating immuno-compromised patients such as
LT recipients. Anti-tumour necrosis factor (TNF)
a agents, have been associated with an increased inci-
dence of either de novo or reactivated systemic infec-
tions.4 Evidence regarding the efficacy and safety of
these biologic agents is very scarce in LT recipients,
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although in a recent systematic review by Westerouen
van Meeteren et al.,5 they are apparently comparable to
those of general post-LT patients.
Even less evidence is available for vedolizumab, a
humanized monoclonal antibody targeting the alpha4-
beta7 integrin, preventing leukocyte trafficking into the
gastrointestinal district.6 Its selective mechanism may
explain the very low incidence of bacterial, mycotic
and viral infections reported in clinical trials and real-
life studies.7 This may suggest vedolizumab as an
attractive option for active IBD in patients who have
previously undergone LT.
To assess the safety of anti-integrin therapy in trans-
plant recipients, we performed a systematic review,
pooling data from the individual initial experiences in
this field.
Methods
The methods of our analysis and inclusion criteria were
based on Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) recommenda-
tions.8 Our protocol was registered with PROSPERO
(www.crd.york.ac.uk/prospero/) on January 2019, after
searching for ongoing systematic reviews (protocol
number: CRD42019120929).
Data sources and search strategy
A comprehensive literature search was performed by
using PubMed, SCOPUS, and EMBASE (up to 30
November 2018) to identify papers, letters and
abstracts, regarding LT recipients and anti-integrin
therapy with vedolizumab. We supplemented the elec-
tronic searches by manual screening of references of
both the included studies and review articles.
We identified studies using the following medical
subject headings (MeSH) and keywords including:
‘liver transplantation’ and ‘Vedolizumab’.
The Medline search strategy was: (‘Vedolizumab’
[Supplementary Concept] OR ‘Vedolizumab’[All Fields])
AND (‘liver transplantation’[MeSH Terms] OR
(‘liver’[All Fields] AND ‘transplantation’[All Fields])
OR ‘liver transplantation’[All Fields]).
Outcome assesment
Primary outcomes were adverse events such as infec-
tions and malignancies on a per patient basis.
Mortality related to infections and malignancies was
also reported. The secondary outcomes were liver trans-
plant outcomes defined as rejection, graft loss, liver-
related mortality and IBD treatment outcomes defined
as clinical response and remission.
Inclusion and exclusion criteria
We considered for inclusion all clinical studies on liver
transplant recipients treated with vedolizumab for IBD.
Studies not reporting the adverse events rate were
excluded. Prospective and retrospective studies, pub-
lished as English-language papers, letters or abstracts,
were considered.
Selection process
Two reviewers (MS and FC) independently performed
the selection process. Full reports were obtained for all
titles meeting the inclusion criteria. Full reports were
retrieved even in case of any uncertainty. Then the
review authors decided whether to include the retrieved
studies by screening the full reports. Disagreements
were resolved by collegial discussion. Neither of the
review authors was blinded to journal titles/study
authors/institutions. In the case of multiple articles
for a single series, we used the latest publication.
Data extraction
Using standardized forms, two reviewers (MS and FC)
extracted data independently. Discrepancies were
resolved by discussion. Two arbitrators (AA and SD)
resolved unresolved disagreements. The following data
were extracted for each study: the study design and
location, the study population and patient characteris-
tics (average age, gender, IBD entity), mean time
between liver transplantation and start of treatment
with vedolizumab, previous biologic therapy, previous
infections, immunosuppressive strategy, mean follow-
up period, number of patients with infections, number
of patients with malignancies, number of patients with
recurrent PSC, number of patients with either clinical
response and remission or none of them and number of
patients with mucosal healing.
Quality assessment
We used the modified Newcastle-Ottawa Scale (NOS)9
for quality assessment. Two reviewers (MS and FC)
assessed quality measures for included studies and dis-
agreements were adjudicated by discussion of all the
authors.
Results
Study characteristics and quality
A total of 81 publications were initially identified
(Figure 1). After the first review process of all the
titles, 11 articles were considered as full text. Of these,
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eight studies matched the inclusion/exclusion criteria
and were finally included.10–17 All studies were pub-
lished between 2016–2018. The study origins were as
follows: six studies were from Europe (25 patients),
and the remains were from Australia (five patients)
and from Argentina (one patient). All the studies
were single-centre experiences.
In total, 31 cases of patients treated with vedolizumab
after LT were reported, most of whom (27/31) were suf-
fering from ulcerative colitis. A new onset IBD was diag-
nosed in eight patients post-transplantation.
The mean age range across the studies was 20.0–47.5
years, most of the patients being male (23/31). The most
common reason for LT was primary sclerosing cholan-
gitis (29/31). Other reasons were autoimmune scleros-
ing cholangitis (one patient) and hepatitis C virus
chronic infection (one patient). Anti-rejection immuno-
suppressive regimens are detailed in Table 1.
Three out of 31 patients underwent the liver trans-
plant while receiving vedolizumab without interruption.
The remaining patients started receiving vedolizumab up
to 159.6 months after LT. Across the four studies report-
ing vedolizumab dosage (18 patients), the initial dosing
was 300mg at weeks 0, 2 and 6 then every eight weeks
thereafter (standard protocol). Three out of 18 patients
needed an optimized maintenance regimen (300mg of
vedolizumab every four weeks).
Overall, 15/32 patients (seven studies) received
anti-TNF agents before anti-integrin treatment, either
pre- or post-LT. The average NOS of the studies was
4.3 (range 3–6). An overview of studies and baseline
characteristics is given in Supplementary Material
Tables 1 and 2.
Primary outcomes
Seven out of 31 patients experienced an infectious event
after a mean time of vedolizumab exposure of 11.4
months (range 5–20 months). In particular, one out of
the five patients included in the series by Peverelle et al.
experienced an episode of Clostridium difficile (CD) col-
itis treated successfully with oral antibiotics.15 The study
by Wright et al. reported a total of 11 infective adverse
events experienced by five patients.14 Four cases of cho-
langitis, four episodes of CD colitis, two empyemas, and
one case of pneumonia occurred. Drastich et al. reported
Medline results
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Figure 1. Flow chart of the study selection process.
LT: liver transplant.
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one patient experiencing mild infective events.16 The
infection type was not specified. No fungal nor viral sys-
temic infections were reported. No deaths occurred
during the period of vedolizumab exposure, but intensive
care monitoring was needed in one case of cholangitis.
Infectious events are briefly reported in Table 2. No
malignancies were reported.
Secondary outcomes
IBD treatment outcomes were reported in eight series
(27 patients). Clinical response was experienced by 21
of 27 patients after a mean follow-up time ranging from
5–20 months. Clinical remission coupled with mucosal
healing was reported in 13 cases. Among the six patients
who did not achieve clinical response, four were referred
for surgery (Supplementary Material Table 3).
LT outcomes were provided by four studies. Among
the 22 patients included, abnormalities in liver bio-
chemistry were recorded in two patients. In both,
liver disease had recurred before vedolizumab initi-
ation. There was a single case of acute cellular rejection
with complete recovery once tacrolimus dose was opti-
mized. Two cases of re-transplant were reported. In
both, liver function had already deteriorated before
vedolizumab initiation because of recurrent PSC and
previous episode of drug-induced liver injury related
to anti-TNF agents.
No cases of liver-related mortality were reported.
Discussion
This systematic review of the available literature pro-
vides data on the safety of vedolizumab therapy in LT
recipients.
Currently, there are limited data on using biological
therapies in this setting. Further, data are mainly
reported in the form of single-centre studies. Hence
this systematic review provides the first comprehensive
point of view on this evolving scenario.
Table 2. Infections.
Reference
Number of
patients
Mean VDZ
exposure time
(months)
Infectionsa
(patients)
Infections
(events) Infections
Hartery 201610 5 6.8 0 0 \
Lim 201611 5 8.1 0 0 \
Wright 201714 10 13.1 5 11 Pneumonia (1),
empyema (2),
CD (4), cholangitis(4)
Olmedo-Martin 201713 2 12.0 0 0 \
Mumtaz 201612 1 8.0 0 0 \
Peverelle 201815 5 20.0 1 1 CD (1)
Drastich 201816 2 6.0 1 NA NA
Daffra 201717 1 5.0 0 0 \
CD: Clostridium difficile; NA: not available; VDZ: vedolizumab.
aNumber of patients who had at least one infection.
Table 1. Anti-rejection immunosuppressive regimens.
Reference Number of patients FK506/CSP AZA/MMF Steroid Singlea Doublea
Hartery 201610 5 5 2 2 3 2
Lim 201611 5 4 2 3 2 2
Wright 201714 10 10 4 2 6 4
Olmedo-Martin 201713 2 2 0 0 2 0
Mumtaz 201612 1 1 1 1 0 1
Peverelle 201815 5 NA NA NA NA NA
Drastich 201816 2 NA NA NA NA NA
Daffra 201717 1 NA NA NA NA NA
AZA: azathioprine; CSP: ciclosporine; FK506: tacrolimus; MMF: mycophenolate.
aSingle and double immunosuppressant therapies were considered irrespectively the steroid assumption.
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A recent meta-analysis has investigated safety of anti-
TNF agents in this setting. The study by Westerouen van
Meeteren et al. found no significant increased in the rate
of serious infection in 52 LT recipients during exposure
to anti-TNF agents5 when compared to non-exposed LT
recipients.
According to our review, seven of the 31 patients
exposed to Vedolizumab experienced infectious
events. In particular, three patients were admitted for
CD infection. Although the colitis was successfully
managed with oral antibiotics in all of the cases, one
patient developed acute cellular rejection in the setting
of immunosuppressant dose reduction. Clinical and
biochemical parameters were restored once the original
tacrolimus dose was resumed.
Since CD colitis is one of the most frequent IBD-
related infections, it might be hasty to blame vedolizu-
mab for these events. Indeed, a low frequency of CD
infections has been reported in vedolizumab trials.3
Furthermore, two of the three patients with CD infec-
tions had already suffered from CD-related colitis prior
to vedolizumab initiation, emphasizing the intrinsic
susceptibility of this subgroup of patient to develop
such infections. Thus it is not surprising to find a simi-
lar incidence of CD infection among the 52 patients
exposed to anti-TNFs in the meta-analysis by
Westerouen van Meeteren et al.5
Just as IBD patients are predisposed to develop intes-
tinal superinfection (i.e. CD colitis), so LT recipients are
at high risk of biliary complications,1 even more so in
cases of PSC recurrence. Hence, as expected, another
important cause of morbidity across the included reports
were cholangitis. Of note, in the study by Wright et al.,
three of the four episodes of cholangitis occurred in
patients with pre-existing percutaneous transhepatic
catheter (PTC) tubes. Both the mechanism specifically
targeting the intestine and the independent risk of
developing infections of such patients, make the role of
vedolizumab probably irrelevant.
Gut selectivity, despite being one of the signature
features of vedolizumab, may still be a reason of con-
cern. In fact the PSC-IBD phenotype typically results in
an increased risk of colorectal cancer and a weakened
local immune vigilance might potentially be a drawback
in this context. Among the included patients no malig-
nancies were reported, but the limited follow-up pre-
vents any definitive conclusion.
Another interesting field to be investigated in the
post-LT setting is the interaction between vedolizumab
pharmacodynamics and PSC developments. Normally,
mucosal vascular addressin cell adhesion molecule 1
(MAdCAM-1) is expressed in the digestive tract endo-
thelium. It is involved in the recruitment of lympho-
cytes expressing integrin a4b7, the target of
vedolizumab. In PSC patients, MAdCAM-1 is also
expressed by hepatic endothelium, encouraging the
recruitment of immune cells. Thus, vedolizumab may
be theoretically considered as a promising therapy for
the treatment of PSC. However, two recent studies18,19
investigated the possible role of vedolizumab in treating
PSC, but none of them found any improvement in
liver biochemistry or disease course. Moreover, a
randomised controlled trial evaluating the efficacy of
vedolizumab for PSC treatment has been stopped pre-
maturely. On the other hand since vedolizumab in IBD
patients is associated with clinical and endoscopic
response, it is not surprising that the included studies
were consistent in reporting a favourable efficacy pro-
file. Data on liver-related outcomes are limited in our
review. Indeed, across the two studies providing such
data two out of 22 patients had abnormalities in liver
biochemistry for recurrent PSC, suggesting the need of
ad-hoc studies pursuing the issue. Nevertheless, the
study by Wright et al. reported that two re-transplant
were needed in LT recipients while being on vedolizu-
mab.14 The reasons for a second transplant were one
case of recurrent PSC and one episode of drug-induced
liver injury related to anti-TNF agents. The authors did
not consider the two cases of graft loss as related to
vedolizumab and both patients remained on biologic
therapy after the new LT. Interestingly, previous art-
icles focusing on IBD patients who underwent LT for
PSC showed a rate of recurrences of up to 50% within
five years,20 with a re-transplantation rate of up to
14.6%.21 In our opinion, the setting of patients with
an unstable graft function has not been sufficiently
investigated to speculate on the role of vedolizumab
in those cases. Indeed, the included series reported
cases with an optimal control of graft function, pre-
venting any definitive conclusion on vedolizumab
safety when the immune balance is still compromised.
The main limitation of our study was the small
sample size, especially if compared with previous stu-
dies reporting safety outcomes in standard IBD
patients. However, LT recipients are invariably
excluded from trials assessing efficacy and safety of
IBD treatments, giving value to the included reports.
Another drawback which needs to be reported is the
high risk of temporal bias, as the time between LT and
vedolizumab exposure among the included patients was
highly heterogeneous. We think that one of the key
points in term of safety is the assessment of the optimal
timing for vedolizumab initiation following LT, a point
that we were unable to assess in our analyses and
deserves future consideration.
Finally, although we compared our results with pre-
vious available findings in IBD patients in post-LT set-
ting, there is a lack of head-to-head comparative studies
between LT recipients undergoing vedolizumab therapy
for IBD and patients undergoing standard
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immunosuppressive therapy alone, for anti-rejection
purposes. However, our study may be a reassuring
background on which to design such comparative
studies.
In conclusion, while awaiting more reliable data,
our study suggests that vedolizumab may be considered
as a safe alternative for treating moderate to severe
IBD in LT recipients. However, caution is recom-
mended for patients with an unstable liver graft func-
tion due to lack of data to support this indication in
this complex setting.
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